Incorporating AI, in silico , and CRISPR technologies to uncover the potential of repurposed drugs in cancer therapy
Hend Gamal, Eman Mostafa Shoeib, Areej Hajjaj, Heba Elsafy Abdelaziz Abdullah, Esmail Elramy, Doaa Ahmed Abd Ellah, Shorouk Mahmoud El-Sayed, Mohammad Fadl Khder · RSC Pharmaceutics · 2025
This figure shows how the integration of AI, in silico methods, and CRISPR technology revolutionizes cancer drug repurposing, enabling efficient discovery and validation of repurposed drugs, accelerating the development of novel cancer therapies.